Abatacept as a Long-Term Targeted Therapy for LRBA Deficiency
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, vol.7, no.8, pp.2790-2815, 2019 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 7 Issue: 8
- Publication Date: 2019
- Doi Number: 10.1016/j.jaip.2019.06.011
- Journal Name: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Page Numbers: pp.2790-2815
- Keywords: LPS-responsive beige-like anchor, Immune dysregulation, Abatacept, T follicular helper cells, Autoimmunity, IMMUNE DYSREGULATION, CTLA-4 CHECKPOINT, MUTATIONS, POLYENDOCRINOPATHY, ENTEROPATHY, DISEASE
- Ondokuz Mayıs University Affiliated: Yes
Abstract
BACKGROUND: LPS-responsive beige-like anchor (LRBA) deficiency presents with susceptibility to infections, autoimmunity, and lymphoproliferation. The long-term efficacy of cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin (abatacept) as targeted therapy for its immune dysregulatory features remains to be established.